A phase 1 clinical trial of venetoclax and rituximab combination therapy was shown to be an effective chemo-free treatment option for patients with difficult-to-treat chronic lymphocytic leukemia.
A newly identified biomarker may predict treatment response in patients with chronic myelogenous leukemia, according to a Northwestern Medicine study.
Nearly 300 principal investigators gathered for a day of discussion and brainstorming to generate transformative ideas that will help guide the Feinberg research enterprise for the next five years.
Northwestern Medicine scientists identified the process by which a calcium channel called the CRAC channel opens and closes, and how mutations in the channel structures that control its opening cause disease.
In recent Northwestern Medicine clinical trials, an experimental drug improved survival rates for patients with advanced midgut neuroendocrine tumors compared to a standard therapy.
A paper published in Molecular Cell provides new insight into a protein complex called COMPASS and its function during histone methylation, a key modification that regulates gene expression.
Joseph Bass, MD, PhD, chief of Endocrinology, Metabolism and Molecular Medicine, focuses his research on illuminating how the body’s clocks regulate feeding behavior and glucose metabolism, and identifies how disruptions in that overarching circadian system play a role in metabolic disease.
Northwestern Medicine scientists showed how the overexpression of the protein SNRK in cardiac tissue improves cardiac metabolism and is protective against ischemic conditions.
Northwestern Medicine scientists presented recent research findings in the field of integrative medicine at the first annual Osher Center Research Day.